Systematic review and meta-analysis on the safety of dalbavancin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Systematic review and meta-analysis on the safety of dalbavancin

Published:2021-06-07 Issue:9 Volume:20 Page:1095-1107
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Monteagudo-Martínez N¹,Solís-García Del Pozo J²^ORCID,Ikuta Ichiro³^ORCID,Galindo Mf⁴^ORCID,Jordán J⁵^ORCID

Affiliation:

1. Department of Pharmacy. Gerencia De Atención Integrada De Villarrobledo, Albacete, Spain

2. Infectious Diseases Unit. Department of Internal Medicine. Gerencia De Atención Integrada De Albacete, Albacete, Spain

3. Department of Radiology & Biomedical Imaging Yale University School of Medicine, New Haven, Connecticut, USA

4. Pharmaceutical Technologic. Medical Sciences Department. Albacete School of Pharmacy. University of Castilla-La Mancha, Albacete, Spain

5. Pharmacology. Medical Sciences Department. Albacete School of Medicine. University of Castilla-La Mancha, Albacete, Spain

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1935864

Reference40 articles.

1. Classification of Nonomuraea sp. ATCC 39727, an actinomycete that produces the glycopeptide antibiotic A40926, as Nonomuraea gerenzanensis sp. nov.

2. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007)

3. Activity of Dalbavancin Tested against Staphylococcus spp. and β-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States

4. In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections

5. Antimicrobial Spectrum and Potency of Dalbavancin Tested Against Clinical Isolates from Europe and North America (2003): Initial Results from an International Surveillance Protocol

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Off-label use of dalbavancin in children: a case series;Journal of Antimicrobial Chemotherapy;2024-07-03

2. Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs;JAC-Antimicrobial Resistance;2024-05-06

3. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study;Journal of Global Antimicrobial Resistance;2024-03

4. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review;Clinical Infectious Diseases;2023-10-15

5. Dalbavancin as Consolidation Therapy in Elderly Patients;European Journal of Geriatrics and Gerontology;2023-08-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3